Economic sustainability of immune-checkpoint inhibitors: the looming threat

Economic sustainability of immune-checkpoint inhibitors: the looming threatEconomic sustainability of immune-checkpoint inhibitors: the looming threat, Published online: 20 August 2018; doi:10.1038/s41571-018-0086-zImmune-checkpoint inhibitors (ICIs) are transforming oncology, but the mounting costs of cancer care necessitate concerns regarding economic sustainability. Here, several strategies that clinicians could use to exercise economically prudent administration of ICIs are discussed. These include better appraisal of the cost-effectiveness literature, judicious patient selection, separating statistical from clinical significance, and careful patient counselling.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research